DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

NEWS RELEASE

Released: January 23, 2023

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Lung Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2023 (FY23)

The FY23 Defense Appropriations Act provides funding for the Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY23 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY23 LCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.

Applications submitted to the FY23 LCRP must address one or more of the following Areas of Emphasis: 

  • Biology and Etiology
    • Understand the molecular mechanisms of initiation and progression to lung cancer.
    • Understand contributors to lung cancer development other than tobacco.
  • Prevention
    • Identify innovative strategies for prevention of the occurrence of lung cancer(s) or subsequent primaries.
    • Identify innovative strategies for the prevention of recurrence or metastases from lung cancer.
  • Detection, Diagnosis, and Surveillance
    • Improve approaches to screening and early detection of lung cancer.
    • Identify strategies for prompt detection and/or characterization of progressive disease.
  • Treatment and Prognosis
    • Identify innovative strategies for the treatment of lung cancer, including overcoming resistance.
    • Develop or optimize biomarkers to assist with therapeutic decision-making.
    • Enhance the treatment and understanding of brain metastases in lung cancer.
  • Health Outcomes and Survivorship
    • Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) with respect to the impact of comorbidities on patient care and also, more broadly, in respect to their effects on patients and their quality of life including, but not limited to, physiological, psychosocial, cognitive, and financial effects.
  • Disparities
    • Advance equity and reduce lung cancer disparities among underserved and underrepresented populations.

Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service Members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the Defense Health Program and FY23 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health: 

  • Use of military of Veteran populations, biospecimens, data/databases, or programs in the proposed research.
  • Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators.
  • Explanation of how the project addresses an aspect of lung cancer that has a direct relevance or is unique to the military, Veterans, other military health system beneficiaries, or family readiness of Service Members, including environmental exposures other than tobacco.

Award Mechanism Eligibility Key Mechanism Elements Funding
Concept Award Investigators at all academic levels
  • Supports highly innovative, non-incremental, high risk/potentially high-reward lung cancer research.
  • Emphasis on innovation.
  • Clinical trials are not allowed.
  • Preliminary data are not required.
  • Relevance to military health is strongly encouraged.
  • Care Delivery and Health Disparity category must address one or more of the Disparities, Health Outcomes, and Survivorship Areas of Emphasis.
  • Cancer Research Continuum category must address at least one or more of the nine cancer continuum-focused Areas of Emphasis.
  • Maximum funding of $100,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 1 year.
Career Development Award


UPDATED!!!
Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment

Mentor:  At or above the level of Associate Professor (or equivalent); have a proven publication and funding record in lung cancer research
  • Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.
  • Clinical trials are not allowed.
  • Preliminary data are not required.
  • Relevance to military health is strongly encouraged.
  • Maximum funding of $375,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 3 years.
Idea Development Award


UPDATED!!!
Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent) or

New Investigators:  Investigators that meet the following criteria by the application submission deadline date:
  • Have not previously received an LCRP Idea Development Award
  • Are within 10 years of first faculty appointment (or equivalent)
  • Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
  • Emphasis on innovation and impact.
  • New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.
  • Clinical trials are not allowed.
  • Preliminary data are required.
  • Relevance to military health is strongly encouraged.
  • Maximum funding of $525,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 3 years.
Translational Research Award


NEW!!!
Investigators at or above the level of Assistant Professor (or equivalent)
  • Supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations.
  • This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:
    • Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts
    • Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug application submission
    • Correlative studies that are associated with an open/ongoing or completed clinical trial
    • Projects that develop endpoints for clinical trials
    • Pilot clinical trials where limited clinical testing (e.g., small sample size) of a novel intervention is necessary to inform the next step in the continuum of translational research
  • Preliminary lung cancer relevant data are required.
  • Relevance to military health is strongly encouraged.

      Level 1

  • Clinical trials are not allowed.

      Level 2

  • Supports translational studies that include a pilot/proof-of-principle clinical trial.
  • Patient research advocate involvement is encouraged.
  Level 1
  • Maximum funding of $900,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 3 years.
  Level 2 – Clinical Trial Option
  • Maximum funding of $1,200,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 4 years.

A pre-application is required and must be submitted through the Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).


Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@health.mil


Last updated Sunday, December 31, 1600